EPCT-15. THE REMIND TRIAL: MULTI-ANTIGEN TARGETED T CELLS FOR PEDIATRIC CNS TUMORS

BACKGROUND: Patients with relapsed CNS malignancies or DIPG face terrible prognoses. We hypothesized that T cells specific for 3 tumor-associated antigens (TAA), WT1, PRAME and survivin, would be safe and elicit anti-tumor immunity. METHODS: Patients (n=9) have received autologous tumor antigen-asso...

Descripción completa

Detalles Bibliográficos
Autores principales: Grant, Melanie, Fortiz, Maria Fernanda, Wang, Lu, Lang, Haili, Datar, Anushree, Reynolds, Emily, Terpilowski, Madeline, Lazarski, Chris, Tanna, Jay, Pitino, Adriana, Zhang, Nan, Hoq, Fahmida, Hanley, Patrick, Kilburn, Lindsay, Packer, Roger, Rood, Brian, Bollard, Catherine, Hwang, Eugene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Early Phase Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715090/
http://dx.doi.org/10.1093/neuonc/noaa222.137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715090/
http://dx.doi.org/10.1093/neuonc/noaa222.137

Ejemplares similares